Finance

Lists
Q3 2026 earnings • released • EPS beat +130.87% • Revenue beat +3.59%
See results
ALKS:NASDAQ
Alkermes Plc
$46.56
+3.73%
(+1.67) 1D
Nov 3, 1:33:45 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ALKS...
Open
$46.17
High
$47.43
Low
$45.22
Mkt. cap
7.81B
Avg. vol.
2.09M
Volume
1.14M
P/E ratio
120.99
52-wk high
$55.67
52-wk low
$27.00
EPS
$0.38
Beta
0.29
Shares outstanding
167.76M
No. of employees
2K
Open
$46.17
High
$47.43
Low
$45.22
Mkt. cap
7.81B
Avg. vol.
2.09M
Volume
1.14M
P/E ratio
120.99
52-wk high
$55.67
52-wk low
$27.00
EPS
$0.38
Beta
0.29
Shares outstanding
167.76M
No. of employees
2K
News stories
From web sources and news partners
Profile
Alkermes plc is a fully-integrated biopharmaceutical company that focuses on developing medicines for psychiatric and neurological disorders. The company was founded in 1987 by Michael Wall. In September 2011 Alkermes, Inc. merged with Elan Drug Technologies, the former drug formulation and manufacturing division of Élan Corporation, plc. The company is headquartered in Dublin, and has an R&D center in Waltham, Massachusetts, and a manufacturing facility in Wilmington, Ohio. Wikipedia
About Alkermes Plc
CEORichard F. Pops | Richard F. Pops
Employees2.05K
Founded1987
Headquarters-
SectorBiotechnology
Websitealkermes.com
Analyst ratings
Based on 12 analysts giving stock ratings to ALKS in the past 3 months
Buy
Buy
8
Hold
3
Sell
1
12-month forecast
Based on 12 Wall Street analysts offering 12 month price targets for ALKS in the last 3 months.
Highest
Current $46.56
$83.00 (+78.25%)
Average
$58.27 (+25.14%)
Lowest
$38.00 (-18.39%)
Analyst
Recommendation
Action
Price target
Projected
Date
Douglas Tsao
H.C. Wainwright
Hold
Maintained
$43.00
-7.7%
11/03/2026
Ami Fadia
Needham
Buy
Reiterated
$62.00
+33.1%
10/19/2026
David Amsellem
Piper Sandler
Buy
Reiterated
$65.00
+39.6%
10/19/2026
Alex Nackenoff
Truist Financial
Buy
Initiated
$55.00
+18.1%
10/16/2026
Unknown Analyst
Truist Financial
Buy
Initiated
$55.00
+18.1%
10/16/2026
Jason Gerberry
Bank of America Securities
Sell
Maintained
$38.00
-18.4%
10/09/2026
Leonid Timashev
RBC Capital
Buy
Maintained
$56.00
+20.3%
10/08/2026
Paul Matteis
Stifel Nicolaus
Buy
Reiterated
$63.00
+35.3%
10/05/2026
Andrea Newkirk
Goldman Sachs
Hold
Initiated
$50.00
+7.4%
09/24/2026
Akash Tewari
Jefferies
Buy
Maintained
$83.00
+78.2%
09/22/2026
Jessica Fye
J.P. Morgan
Hold
Maintained
-
-
09/21/2026
Luke Herrmann
Robert W. Baird
Buy
Maintained
$61.00
+31%
09/22/2026
Graig Suvannavejh
Mizuho Securities
Buy
Maintained
$65.00
+39.6%
09/22/2026
Uy Ear
Mizuho Securities
Buy
Maintained
$65.00
+39.6%
09/04/2026
Benjamin Burnett
Wells Fargo
Buy
Reiterated
$65.00
+39.6%
07/29/2026
Joseph Thome
TD Cowen
Buy
Maintained
$58.00
+24.6%
07/28/2026
Unknown Analyst
Wells Fargo
Buy
Maintained
$44.00
-5.5%
05/13/2026
Ashwani Verma
UBS
Buy
Maintained
$48.00
+3.1%
05/06/2026
Marc Goodman
Leerink Partners
Hold
Maintained
-
-
03/31/2026
Pete Stavropoulos
Cantor Fitzgerald
Buy
Maintained
$43.00
-7.7%
03/11/2026
Joon Lee
Truist Financial
Buy
Maintained
-
-
02/26/2026
Rudy Li
Wolfe Research
Buy
Initiated
$45.00
-3.4%
02/23/2026
Last report
Just released
Today, 3:00 PM
Fiscal period
Q3 2026
$0.57 / $0.25
+130.87%beat
Revenue / Est. (USD)
480.13M / 463.48M
+3.59%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
394.18M
384.55M
392.91M
496.01M
Cost of goods sold
51.59M
46.21M
48.85M
67.11M
Cost of revenue
51.59M
46.21M
48.85M
67.11M
Research and development expenses
78.54M
89.74M
100.08M
109.58M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
174.97M
190.50M
233.06M
219.86M
Operating expense
253.51M
280.23M
344.81M
352.03M
Total operating expenses
305.10M
326.44M
393.66M
419.14M
Operating income
89.08M
58.10M
-754.00K
76.87M
Other non operating income
-280.00K
1.42M
-1.29M
852.00K
EBT including unusual items
100.74M
60.38M
-61.93M
-1.88M
EBT excluding unusual items
100.74M
60.38M
-14.40M
57.14M
Income tax expense
17.98M
11.04M
4.55M
-2.38M
Effective tax rate
17.85%
18.28%
-7.35%
126.71%
Other operating expenses
-
-
-
-
Net income
82.76M
49.34M
-66.48M
501.00K
Net profit margin
21.00%
12.83%
-16.92%
0.10%
Earnings per share
0.65
0.48
0.38
0.70
Interest and investment income
11.94M
12.13M
8.54M
5.34M
Interest expense
-
-12.28M
-20.89M
-25.92M
Net interest expenses
11.94M
-147.00K
-12.35M
-20.58M
Depreciation and amortization charges
-
-
-
-
EBITDA
97.16M
61.95M
18.68M
107.14M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps